Your Health, We Care
Multiple international treatment guidelines, including the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO), have listed Capmatinib as the first-line treatment of METex14 skipping NSCLC.
In the 2024 CSCO guidelines for the diagnosis and treatment of non-small cell lung cancer, Capmatinib is also recommended for first-line treatment of MET ex14 jumping mutation non-small cell lung cancer.
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells···【more】
Release date：2024-08-07Recommended：91
Capmatinib is highly selective for c-Met targets, can effectively inhibit the pr···【more】
Release date：2024-08-07Recommended：120
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or t···【more】
Release date：2024-08-06Recommended：97
